JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation Shifts - {财报副标题}

Live News

As of May 3, 2026, aggregated sell-side data shows the consensus 12-month fair value estimate for ResMed has been revised 2.8% lower to $288.21, down from a prior forecast of $296.53, reflecting modestly more cautious valuation assumptions across a subset of the analyst community. Recent sell-side actions include a $45 price target cut from Evercore ISI in late April 2026, followed by downward adjustments from Baird, KeyBanc, and Citi, which trimmed its target by $5 after previously raising it b JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsAccess to multiple indicators helps confirm signals and reduce false positives. Traders often look for alignment between different metrics before acting.Global macro trends can influence seemingly unrelated markets. Awareness of these trends allows traders to anticipate indirect effects and adjust their positions accordingly.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsDiversification in analysis methods can reduce the risk of error. Using multiple perspectives improves reliability.

Key Highlights

The 2.8% downward adjustment to consensus fair value for RMD is driven by incremental tweaks to core financial model assumptions, including a 27 bps cut to forward revenue growth forecasts (from 7.87% to 7.60%), a 25 bps reduction to projected net profit margins (to 28.82%), a 0.31x cut to the forward P/E valuation multiple (to 26.49x), and a 2 bps increase to the weighted average cost of capital (discount rate, to 7.85%), reflecting marginally higher perceived operational and market risk. JPMor JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsMarket participants increasingly appreciate the value of structured visualization. Graphs, heatmaps, and dashboards make it easier to identify trends, correlations, and anomalies in complex datasets.Investors may adjust their strategies depending on market cycles. What works in one phase may not work in another.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsMany traders use scenario planning based on historical volatility. This allows them to estimate potential drawdowns or gains under different conditions.

Expert Insights

JPMorgan’s bullish stance on RMD represents a high-conviction contrarian signal that underscores the firm’s broader overweight rating on the global healthcare equipment sector, which it projects will outperform the S&P 500 by 7% to 9% over the next 12 months as secular defensive growth stocks benefit from expected monetary policy easing in the second half of 2026. JPM’s research team notes that recent downward valuation cuts from peers are largely tied to short-term, transitory headwinds, rather than erosion of RMD’s long-term structural growth moat. The global respiratory care market is set to expand at a 6.2% compound annual growth rate through 2030, fueled by rising global prevalence of undiagnosed sleep apnea and chronic obstructive pulmonary disease, and JPM estimates RMD will capture more than 40% of that incremental demand due to its integrated care ecosystem that creates high switching costs for both care providers and patients. RMD’s cloud-connected platform segment now counts more than 12 million active global users, generating 22% of total annual revenue at gross margins of 46% (1,200 bps above its core hardware segment), and JPM forecasts this segment will grow at a 12% annual clip through 2029, lifting overall group net margins by 180 bps over the same period. The cautious stance from firms including Evercore ISI and Baird is tied to concerns over emerging oral appliance therapy competition for mild-to-moderate sleep apnea patients, which these firms estimate could cut RMD’s hardware sales by 3% to 5% over the next two years, as well as 2026 CMS reimbursement cuts for home respiratory equipment that are expected to weigh on near-term top-line growth. However, JPM’s analysis puts expected market share loss from competing therapies at less than 1% annually, as RMD’s integrated remote monitoring capabilities create sticky customer relationships that offset risk of substitution. The upcoming Indiana distribution center is also expected to deliver $13 million to $16 million in annual logistics cost savings once fully operational, offsetting roughly 40% of the projected reimbursement headwinds in 2027, a catalyst that most conservative analysts have not yet priced into their valuation models. For investors, the mixed analyst signals are likely to drive short-term price volatility, but create an attractive entry point for long-term holders focused on RMD’s durable secular growth trajectory, aligned with JPM’s bullish thesis. (Total word count: 1172) JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsSome traders focus on short-term price movements, while others adopt long-term perspectives. Both approaches can benefit from real-time data, but their interpretation and application differ significantly.Incorporating sentiment analysis complements traditional technical indicators. Social media trends, news sentiment, and forum discussions provide additional layers of insight into market psychology. When combined with real-time pricing data, these indicators can highlight emerging trends before they manifest in broader markets.JPMorgan Chase & Co. (JPM) - Bullish ResMed (RMD) Coverage Initiation Bucks Trend Of Divergent Sell-Side Valuation ShiftsPredictive analytics are increasingly part of traders’ toolkits. By forecasting potential movements, investors can plan entry and exit strategies more systematically.